SAFETY OF BIOPHARMACEUTICALS: FACING NEW REALITIES

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background: A greatnumber of biopharmaceuticals has been implemented for clinical practice in recent years. Clinical relevance of these drugs is increasing. Results: Authors made a systematic review of adverse events of biopharmaceuticals from 1990 to 2014. We searched information about safety of biopharmaceuticals in international data bases. Inclusion criteria were safety profile of immunodepressant and antitumor drugs. Conclusion: We determine the difference between biopharmaceuticals and small molecules in case of adverse events. Adverse event classification was assessed. We made a guideline for Russian Pharmacovigilance System.

Full Text

Restricted Access

About the authors

A S Kolbin

First Pavlov State Medical University of St. Petersburg; St. Petersburg State University


A A Toporov

First Pavlov State Medical University of St. Petersburg

Email: zenoantaneho@gmail.com

References

  1. Motola D., De Ponti F., Poluzzi E. et al. An update on the first decade of the European centralized procedure: how many innovative drugs? // Br. J. Clin. Pharmacol. - 2006. - Vol. 62 (5). - Р. 610-616.
  2. Trusheim M.R., Aitken M.L., Berndt А.R. Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? // Forum Health Econ Pol. - 2010. - Vol. 13(1). - Р. 1-45.
  3. www.bio.org
  4. Астахова А.В., Лепахин В.К. Федеральный центр мониторинга безопасности лекарственных средств. Роль системы управления рисками в профилактике осложнений фармакотерапии http://www.rspor.ru.
  5. Кaloramainformation // www.kaloramainformation.com (дата обращения 15.02.2015).
  6. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies // Clin Dermatol. - 2010. - Vol. 28 (1). - Р. 88-92.
  7. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs // Ann. Rheum Dis. - 2010. - Vol. 69 (6). - Р. 964-975.
  8. Pathirana D., Ormerod А.D., Saiag P. et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris // J. Eur. Acad. Dermatol. Venereol. - 2009. - Vol. 23 (Suppl. 2). - Р. 1-70.
  9. Singh J., Christensen R., Wells G.А. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews // Cochrane Database Syst Rev. - 2009. - Vol. (4). - CD007848.
  10. Alonso-Ruiz А., Pijoan J.I., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety // BMC Musculo skelet Disord. - 2008. - Vol. 9. - Р. 52.
  11. Мазуров В.И. Клиническая ревматология. Руководство для практических врачей. - 2-е изд. - СПб.: Фолиант, 2005. - 520 с.
  12. Интернет-портал Российского общества клинической онкологии в составе проекта Oncology.ru // www.rosoncoweb.ru (дата обращения 15.02.2015).
  13. Aronson J.K. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. Stephens’ Detection and evaluation of adverse drug reactions. - New York: Wiley Ltd, 2011. - Р. 1-119.
  14. Clark J.B. Mechanisms of adverse drug reactions to biologics // Adverse drug reactions / ed. J. Uetrecht. - Berlin: Springer, 2010. - Р. 453-474.
  15. Baumann А. Early development of therapeutic biologics: pharmacokinetics // Curr. Drug. Metab. - 2006. - Vol. 7(7). - Р. 15-21.
  16. Giezen T.J., Mantel-Teeuwisse А.K., Leufkens H.G. Pharmacovigilance of biopharmaceuticals: challenges remain // Drug Saf. - 2009. - Vol. 32 (10). - Vol. 811-817.
  17. Doran M.F., Crowson C.S., Pond G.R. et al. Predictors of infection in rheumatoid arthritis // Arthritis Rheum. - 2002. - Vol. 46 (9). - Р. 2294-300.
  18. Колбин А.С., Курылев А.А., Павлыш А.В. и др. Научный анализ исходов в онкологии. Особенности фармакоэкономической экспертизы // Медицинские технологии. Оценка и выбор. - 2012. - № 2 (8). - С. 87-93.
  19. Kleijnen S., George E., Goulden S. et al. Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions // Value In Health. - 2012. - Vol. 15. - Р. 954-960.
  20. Vial T., Descotes J. Immunosuppressive drugs and cancer // Toxicology. - 2003. - Vol. 185 (3). - Р. 229-240.
  21. Лепахин В.К., Ушакова Е.А., Астахова А.В. Роль клинического фармаколога в повышении безопасности лекарственной терапии // Безопасность лекарств и фармаконадзор. - 2008. - № 1. - C. 5-11.
  22. Giezen T.J., Mantel-Teeuwisse A.K., Meyboom R.H. et al. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database // VigiBase. Drug Saf. - 2010. - Vol. 33 (10). - Р. 865-878.
  23. Giezen T.J., Mantel-Teeuwisse A.K., Straus S.M. et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union // JAMA. - 2008. - Vol. 300(16). - Р. 1887-1896.
  24. Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials // JAMA. - 2006. - Vol. 295(19). - Р. 2275-2285.
  25. www.fda.gov
  26. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl. - 2009. - Vol. 82. - Р. 25-32.
  27. Colombel J.F., Sandborn W.J., Ghosh S. et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3 // Am. J. Gastroenterol. - 2014. - Vol. 109. - Р. 1771-1780.
  28. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects // Clin Ther. - 2002. - Vol. 24 (11). - Р. 1720.
  29. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins // Nephrol Dial Transplant. - 2005. - Vol. 20, Suppl. 6. - Р. vi3-9.
  30. Locatelli F., Del Vecchio L., Pozzoni P. Pure red-cell aplasia «epidemic» - mystery completely revealed? // Perit Dial Int. - 2007. - Vol. 27, Suppl. 2. - Р. S303-307.
  31. Schiffmann R., Pastores G., Lien Y.H. et al. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study // Orphanet J. of Rare Diseases. - 2014. - Vol. 9. - Р. 169.
  32. Pastores G., Rosenbloom B., Weinreb N. et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability // Genet Med. - 2014. - Vol. 16(5). - Р. 359-366.
  33. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials // Ann. Rheum Dis. - 2009. - Vol. 68 (1). - Р. 25-32.
  34. Zhou Z., Chen C., Zhang J. et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis // Int. J. Clin. Exp Pathol. - 2014. - Vol. 7 (5). - Р. 2113-2122.
  35. Bykerk V., Cush J., Winthrop K. et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials // Ann. Rheum. Dis. - 2015. - Vol. 74. - Р. 96-103.
  36. Keane J., Gershon S., Wise R.P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent // N. Engl. J. Med. - 2001. - Vol. 345(15). - Р. 1098-104.
  37. Slifman N.R., Gershon S.K., Lee J.H. et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents // Arthritis Rheum. - 2003. - Vol. 48 (2). - Vol. 319-324.
  38. Dale R., Brilot F., Duffy L. et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease // Neurology. - 2014. - Vol. 83(2). - Р. 142-150.
  39. Kanegane H., Imai K., Yamada M. et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin in Japanese patients with primary immunodeficiency diseases // J. Clin. Immunol. - 2014. - Vol. 34. - Р. 204-211.
  40. Westin J., Chu F., Zhang M. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial // Lancet Oncol. - 2014. - Vol. 15(1). - Р. 69-77.
  41. Huizinga T., Fleischmann R., Jasson M. et al. Sarilumab - fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomized SARIL-RA-MOBILITY Part A trial // Ann Rheum Dis. - 2014. - Vol. 73. - Р. 1626-1634.
  42. Dixon W.G., Watson K., Lunt M. et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register // Arthritis Rheum. - 2006. - Vol. 54 (8). - Р. 2368-2376.
  43. Schneeweiss S., Setoguchi S., Weinblatt M.E. et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. - 2007. - Vol. 56 (6). - Р. 1754-1764.
  44. Curtis J.R., Patkar N., Xie A. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists // Arthritis Rheum. - 2007. - Vol. 56 (4). - Vol. 1125-1133.
  45. Suwannalai P., Auethavekiat P., Udomsubpayakul U. et al. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital // Int. J. Rheum Dis. - 2009. - Vol. 12 (2). - Р. 118-124.
  46. Strangfeld A., Listing J., Herzer P. et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents // JAMA. - 2009. - Vol. 301 (7). - Р. 737-744.
  47. Ebbers H.C., Al-Temimi E., Moors E.H. et al. Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules // BioDrugs. - 2013 doi: 10.1007/s40259-013-0012-y.
  48. Lasser K.E., Allen P.D., Woolhandler S.J. et al. Timing of new black box warnings and withdrawals for prescription medications // JAMA. - 2002. - Vol. 287 (17). - Р. 2215-2220.
  49. Crommelin D.J., Storm G., Verrijk R. et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs // Int. J. Pharm. - 2003. - Vol. 266(1-2). - Р. 3-16.
  50. Schellekens H. How similar do ‘biosimilars’ need to be? // Nat Biotechnol. - 2004. - Vol. 22 (11). - Р. 1357-1359.
  51. Brennan F.R., Shaw L., Wing M.G. et al. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges // Mol Biotechnol. - 2004. - Vol. 27 (1). - Р. 59-74.
  52. EIDOS: a mechanistic classification of adverse drug effects // Drug Saf. - 2010. - Vol. 33 (1). - Р. 15-23.
  53. Pichler W.J. Adverse side-effects to biological agents // Allergy. - 2006. - Vol. 61 (8). - Р. 912-920.
  54. Shankar G., Pendley C., Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs // Nat. Biotechnol. - 2007. - Vol. 25 (5). - Р. 555-561.
  55. Hausmann O.V., Seitz M., Villiger P.M. et al. The complex clinical picture of side effects to biologicals // Med. Clin North Am. - 2010. - Vol. 94 (4). - Р. 791-804.
  56. Zemková M., Jebavý L., Kotlárová J. et al. The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification // Folia Biol (Praha). - 2007. - Vol. 53 (4). - Р. 146-155.
  57. Колбин А.C., Бурбелло А.T., Загородникова K.А. Фармаконадзор в Российской Федерации и в Объединенной Европе в свете новой директивы Евросоюза. Ждут ли нас изменения? // Ремедиум. - 2012. - № 8 (186). - C. 8-14.
  58. Fitt H. The new pharmacovigilance legislation: an EMA perspective. - IPA Conference Reinforcing patient safety in Europe. - 2011. Опубликовано онлайн: URL :www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/06/WC500107888.pdf (доступ 05.07.12).
  59. The European Parliament and the Council of the European Union. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products [online]. URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=0J:L:2010:348:0001:0016:EN:PDF (доступ 05.07.12).
  60. Mellstedt H., Niederwieser D., Ludwig H. The challenge of biosimilars // Ann Oncol. - 2008. - Vol. 19 (3). - Р. 411-419.
  61. Zuniga L., Calvo B. Biosimilars: pharmacovigilance and risk management // Pharmacoepidemiol Drug Saf. - 2010. - Vol. 19 (7). - Р. 661-669.

Statistics

Views

Abstract - 79

PDF (Russian) - 3

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2015 Kolbin A.S., Toporov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies